Chinese cosmetics group best known for its Winona sensitive-skin skincare brand.
Chinese cosmetics group best known for its Winona sensitive-skin skincare brand.
Earns most of its income from Winona, sold largely online through Chinese e-commerce platforms and also through pharmacies, so one brand carries the group while its other skincare lines and baby care stay secondary. Marketing to win shoppers on those platforms is a major cost.
In one line: A Chinese dermo-cosmetics company, like a domestic La Roche-Posay owner.
Moat: narrow (brand). Winona's leading position in China's sensitive-skin/dermo-cosmetics niche differentiates it from mass-market beauty brands.
Headquarters: Shanghai, China · Founded: 2003 · Employees: 3,508
Size Shanghai Chicmax Cosmetics (2145.HK) is a Hong Kong Consumer Staples company (Household/Personal Care) with a market value of $1.17B, the 545th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$23.32 on 18 Nov 2026.
Performance Over six months the shares fell 42.1%, against +10.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 23.2% over the last twelve months (peer median +8.8%); the operating margin is 7.5% (peer median 9.2%).
Valuation It trades at 14.4× forward earnings against a peer median of 19.8× (5th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -27 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.7 points above its cost of capital (6.3% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$9.83B | HK$9.95B | HK$7.36B | HK$4.63B | HK$3.11B |
| Revenue growth | — | +35% | +59% | +49% | — |
| Gross profit | HK$7.57B | HK$7.61B | HK$5.54B | HK$3.34B | HK$1.98B |
| EBITDA | HK$1.02B | HK$1.37B | HK$866M | HK$587M | HK$181M |
| Net income | HK$757M | HK$1.20B | HK$847M | HK$510M | HK$171M |
| Free cash flow | HK$594M | HK$746M | HK$333M | HK$697M | -HK$31.1M |
| Capital expenditure | HK$661M | HK$558M | HK$263M | HK$97.8M | HK$69.9M |
| Total debt | n/a | HK$704M | HK$119M | HK$182M | HK$818M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai Chicmax Cosmetics 2145.HK | $1.17B | -42% | +23% | 8% | 14.4× | -6.1% |
| Giant Biogene 2367.HK | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% |
| Proya Cosmetics 603605.SS | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% |
| L'Oreal OR.PA | $259B | +20% | +3% | 21% | 32.3× | 18.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2145.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.4% | -1.6% | 10th highest of 21 |
| 6-month return | -42.1% | +10.5% | 3rd lowest of 21 |
| Distance from 52-week high | -74.1% | -27.4% | lowest of 21 |
| Revenue growth (TTM) | +23.2% | +8.8% | 7th highest of 21 |
| Operating margin | 7.5% | 9.2% | 7th lowest of 21 |
| Forward P/E | 14.4× | 19.8× | 5th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -6.1% | 4.3% | 3rd least demanding of 18 |
| Growth delivered (Del g) | +21.2% | +8.9% | 5th highest of 18 |
| Hurdle (Req g minus delivered) | -27.3 pp | -4.4 pp | 3rd least demanding of 18 |
| ROIC minus cost of capital | +13.7 pp | +7.1 pp | 7th highest of 21 |
| EV / EBITDA | 9.0× | 10.4× | 4th cheapest of 12 |
| Net debt / EBITDA | -0.2× | -1.2× | 4th most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Chicmax Cosmetics 2145.HK | Hong Kong | $1.17B | -42% | +23% | 8% | 14.4× | -6.1% | +21.2% |
| d'Alba Global 483650.KS | South Korea | $1.13B | -55% | +49% | 22% | 12.0× | -6.6% | +53.0% |
| Edgewell Personal Care EPC | United States | $1.30B | +67% | -10% | 7% | 14.2× | n/a | n/a |
| Shanghai Forest Cabin Cosmetics 2657.HK | Hong Kong | $1.04B | +15% | +74% | 18% | 11.8× | 11.3% | +49.0% |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.35B | +27% | 0% | 3% | 37.3× | 28.8% | +22.8% |
| Noevir 4928.T | Japan | $978M | +7% | -3% | 28% | 20.4× | -12.8% | +4.1% |
| Intercos ICOS.MI | Italy | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% | +11.5% |
| Tongling Jieya Biologic Technology 301108.SZ | China | $933M | +56% | +24% | 5% | 52.5× | 28.5% | +0.8% |
| Runben Biotechnology 603193.SS | China | $918M | -30% | +13% | 21% | 18.5× | 1.5% | +28.4% |
| Dencare (Chongqing) Oral Care 001328.SZ | China | $912M | +13% | +10% | 11% | 27.9× | 3.7% | +10.8% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.51B | -39% | +28% | 20% | 21.4× | 7.5% | +3.6% |
| AMOREPACIFIC 002790.KS | South Korea | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% | -1.3% |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |
| Cosmecca Korea 241710.KS | South Korea | $847M | +23% | +42% | 12% | 16.3× | n/a | n/a |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |
| Galaxy Surfactants GALAXYSURF.NS | India | $845M | +22% | +30% | 9% | 17.6× | 18.5% | +13.7% |
| SYoung 300740.SZ | China | $816M | -48% | +14% | 3% | 33.4× | 14.0% | +6.1% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| Jyothy Labs JYOTHYLAB.NS | India | $762M | -9% | +5% | 8% | 40.8× | 34.5% | +8.9% |
| Milbon 4919.T | Japan | $743M | +48% | +8% | 14% | 25.7× | -3.3% | +8.2% |